Breast Imaging Market Size, Share & Trends Analysis Report By Technology (Ionizing, Non Ionizing), By End Use (Hospitals, Breast Care Centers, Diagnostic Imaging Centers), By Region, And Segment Forecasts, 2026 - 2033
Description
Breast Imaging Market Summary
The global breast imaging market size was estimated at USD 5.88 billion in 2025 and is projected to reach USD 12.03 billion by 2033, growing at a CAGR of 9.7% from 2026 to 2033. Factors such as the rising prevalence of breast cancer, technological breakthroughs in the domain of breast imaging, and investment from several organizations in breast cancer screening programs drive the breast imaging market.
According to the World Cancer Research Fund (WCRF), by 2030, the number of cases of breast cancer is expected to reach about 2.1 million globally. According to a new report from the International Agency for Research on Cancer (IARC), breast cancer cases are expected to increase by 38 percent globally by 2050, with annual deaths from the disease projected to rise by 68 percent. This aspect is expected to contribute to the growth of the breast imaging market over the forecast period.
The growing prevalence of breast cancer and other breast-related abnormalities is expected to drive the expansion of the breast imaging market significantly. According to data published by the National Breast Cancer Foundation, Inc. in June 2025, approximately 1 in 8 women in the U.S. is expected to be diagnosed with breast cancer during their lifetime. In addition, projections from the International Agency for Research on Cancer estimate a 27.8% increase in breast cancer incidence in the U.S. between 2022 and 2050, with cases expected to reach approximately 350,693 by 2050. This substantial rise in cancer cases is anticipated to fuel the demand for breast magnetic resonance imaging procedures across the country.
Technological advancements are driving the growth of the breast imaging market, supported by increasing demand for earlier and more accurate cancer detection. Innovations such as molecular breast imaging, AI-assisted diagnostics, and enhanced breast imaging displays are improving clinical confidence and reducing interpretation challenges. As healthcare providers prioritize precision medicine and screening efficiency, these advanced tools continue to accelerate adoption and shape the future of breast cancer detection and care.
Widespread research in the development of hybrid imaging systems provides high growth opportunities and also aids the market growth. Recent developments in imaging technology have completely revolutionized the nature of treatment and how it is approached. To view the metabolic data and anatomical characteristics of the organs, it has become more crucial to combine imaging methods such as CT scans, MRIs, PET, and others. Furthermore, the quality of breast pictures, patient comfort, and patient dose have all been enhanced by these integrated imaging modalities. Thereby, owing to these advantages, manufacturers across the globe are concentrating more on the introduction of new products to improve the sensitivity and precision of breast cancer diagnostics. For instance, in February 2025, DeepHealth plans to introduce its Diagnostic Suite to the European market, offering a next-generation PACS system with a unified, workflow-optimized radiology workspace. The company also aims to expand access to SmartMammo, its AI-driven end-to-end mammography diagnostic solution, further integrating AI-enabled detection and clinical decision support into routine imaging workflows.
Global Breast Imaging Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global breast imaging market report based on technology, end use, and region:
The global breast imaging market size was estimated at USD 5.88 billion in 2025 and is projected to reach USD 12.03 billion by 2033, growing at a CAGR of 9.7% from 2026 to 2033. Factors such as the rising prevalence of breast cancer, technological breakthroughs in the domain of breast imaging, and investment from several organizations in breast cancer screening programs drive the breast imaging market.
According to the World Cancer Research Fund (WCRF), by 2030, the number of cases of breast cancer is expected to reach about 2.1 million globally. According to a new report from the International Agency for Research on Cancer (IARC), breast cancer cases are expected to increase by 38 percent globally by 2050, with annual deaths from the disease projected to rise by 68 percent. This aspect is expected to contribute to the growth of the breast imaging market over the forecast period.
The growing prevalence of breast cancer and other breast-related abnormalities is expected to drive the expansion of the breast imaging market significantly. According to data published by the National Breast Cancer Foundation, Inc. in June 2025, approximately 1 in 8 women in the U.S. is expected to be diagnosed with breast cancer during their lifetime. In addition, projections from the International Agency for Research on Cancer estimate a 27.8% increase in breast cancer incidence in the U.S. between 2022 and 2050, with cases expected to reach approximately 350,693 by 2050. This substantial rise in cancer cases is anticipated to fuel the demand for breast magnetic resonance imaging procedures across the country.
Technological advancements are driving the growth of the breast imaging market, supported by increasing demand for earlier and more accurate cancer detection. Innovations such as molecular breast imaging, AI-assisted diagnostics, and enhanced breast imaging displays are improving clinical confidence and reducing interpretation challenges. As healthcare providers prioritize precision medicine and screening efficiency, these advanced tools continue to accelerate adoption and shape the future of breast cancer detection and care.
Widespread research in the development of hybrid imaging systems provides high growth opportunities and also aids the market growth. Recent developments in imaging technology have completely revolutionized the nature of treatment and how it is approached. To view the metabolic data and anatomical characteristics of the organs, it has become more crucial to combine imaging methods such as CT scans, MRIs, PET, and others. Furthermore, the quality of breast pictures, patient comfort, and patient dose have all been enhanced by these integrated imaging modalities. Thereby, owing to these advantages, manufacturers across the globe are concentrating more on the introduction of new products to improve the sensitivity and precision of breast cancer diagnostics. For instance, in February 2025, DeepHealth plans to introduce its Diagnostic Suite to the European market, offering a next-generation PACS system with a unified, workflow-optimized radiology workspace. The company also aims to expand access to SmartMammo, its AI-driven end-to-end mammography diagnostic solution, further integrating AI-enabled detection and clinical decision support into routine imaging workflows.
Global Breast Imaging Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global breast imaging market report based on technology, end use, and region:
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Ionizing
- Full-field Digital Mammography
- Analog Mammography
- Positron Emission Mammography
- Electric Impedance Tomography
- Cone-beam Computed Tomography
- Positron Emission Tomography & Computed Tomography
- 3D Breast Tomosynthesis
- MBI/BSGI
- Non Ionizing
- MRI
- Thermography
- Ultrasound
- Optical Imaging
- Automated Whole-Breast Ultrasound
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Breast Care Centers
- Diagnostic Imaging Centers
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
97 Pages
- Chapter 1. Research Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Regional scope
- 1.1.2. Component
- 1.1.3. Technology
- 1.1.4. Application
- 1.1.5. End Use
- 1.2. Estimates and forecast timeline.
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database.
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Component
- 2.2.2. Technology
- 2.2.3. Application
- 2.2.4. End Use
- 2.2.5. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Computational Pathology Market Variables, Trends & Scope
- 3.1. Market Dynamics
- 3.1.1. Market driver analysis
- 3.1.1.1. Increasing prevalence of chronic diseases
- 3.1.1.2. Higher cost-efficiency
- 3.1.1.3. Rapid technological advancements in computational pathology
- 3.1.1.4. Emergence of Quantitative Continuous Scoring (QCS) in digital pathology
- 3.1.2. Market restraint analysis
- 3.1.2.1. High cost of implementing digital and computational pathology solutions
- 3.1.2.2. Stringent regulatory requirements
- 3.1.3. Market Opportunity Analysis
- 3.1.4. Market Challenge Analysis
- 3.2. Case Study Insights
- 3.3. Computational Pathology Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
- 3.3.3. Technology Trends Analysis
- Chapter 4. Computational Pathology Market: Component Estimates & Trend Analysis
- 4.1. Component Market Share, 2025 & 2033
- 4.2. Segment Dashboard
- 4.3. Global Computational Pathology Market by Component Outlook
- 4.4. Software
- 4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.5. Services
- 4.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Computational Pathology Market: Application Estimates & Trend Analysis
- 5.1. Application Market Share, 2025 & 2033
- 5.2. Segment Dashboard
- 5.3. Global Computational Pathology Market by Application Outlook
- 5.4. Disease Diagnosis
- 5.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.5. Drug Discovery & Development
- 5.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.6. Academic Research
- 5.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Computational Pathology Market: Technology Estimates & Trend Analysis
- 6.1. Technology Market Share, 2025 & 2033
- 6.2. Segment Dashboard
- 6.3. Global Computational Pathology Market by Technology Outlook
- 6.4. Machine Learning (ML)
- 6.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.2. Deep Learning
- 6.4.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.3. Supervised
- 6.4.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.4. Unsupervised
- 6.4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.4.5. Others
- 6.4.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.5. Natural Language Processing (NLP) Models
- 6.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.6. Computer Vision
- 6.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.7. Others
- 6.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Computational Pathology Market: End Use Estimates & Trend Analysis
- 7.1. End Use Market Share, 2025 & 2033
- 7.2. Segment Dashboard
- 7.3. Global Computational Pathology Market by End Use Outlook
- 7.4. Hospitals and Diagnostic Labs
- 7.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.5. Biotechnology and Pharmaceutical Companies
- 7.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.6. Academic and Research Institutes
- 7.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- 7.7. Others
- 7.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Computational Pathology Market: Regional Estimates & Trend Analysis, By Component, By Application, By Technology, By End Use
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Global Regional Market Snapshot
- 8.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 8.5. North America
- 8.5.1. U.S.
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework
- 8.5.1.3. Competitive scenario
- 8.5.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.5.2. Canada
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework
- 8.5.2.3. Competitive scenario
- 8.5.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Mexico
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework
- 8.5.3.3. Competitive scenario
- 8.5.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.6. Europe
- 8.6.1. UK
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework
- 8.6.1.3. Competitive scenario
- 8.6.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Germany
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework
- 8.6.2.3. Competitive scenario
- 8.6.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.6.3. France
- 8.6.3.1. Key country dynamics
- 8.6.3.2. Regulatory framework
- 8.6.3.3. Competitive scenario
- 8.6.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.6.4. Italy
- 8.6.4.1. Key country dynamics
- 8.6.4.2. Regulatory framework
- 8.6.4.3. Competitive scenario
- 8.6.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Spain
- 8.6.5.1. Key country dynamics
- 8.6.5.2. Regulatory framework
- 8.6.5.3. Competitive scenario
- 8.6.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.6.6. Norway
- 8.6.6.1. Key country dynamics
- 8.6.6.2. Regulatory framework
- 8.6.6.3. Competitive scenario
- 8.6.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Sweden
- 8.6.7.1. Key country dynamics
- 8.6.7.2. Regulatory framework
- 8.6.7.3. Competitive scenario
- 8.6.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.6.8. Denmark
- 8.6.8.1. Key country dynamics
- 8.6.8.2. Regulatory framework
- 8.6.8.3. Competitive scenario
- 8.6.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.7. Asia Pacific
- 8.7.1. Japan
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework
- 8.7.1.3. Competitive scenario
- 8.7.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.7.2. China
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework
- 8.7.2.3. Competitive scenario
- 8.7.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.7.3. India
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Regulatory framework
- 8.7.3.3. Competitive scenario
- 8.7.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.7.4. Australia
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Regulatory framework
- 8.7.4.3. Competitive scenario
- 8.7.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.7.5. South Korea
- 8.7.5.1. Key country dynamics
- 8.7.5.2. Regulatory framework
- 8.7.5.3. Competitive scenario
- 8.7.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.7.6. Thailand
- 8.7.6.1. Key country dynamics
- 8.7.6.2. Regulatory framework
- 8.7.6.3. Competitive scenario
- 8.7.6.4. Singapore market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.8. Latin America
- 8.8.1. Brazil
- 8.8.1.1. Key country dynamics
- 8.8.1.2. Regulatory framework
- 8.8.1.3. Competitive scenario
- 8.8.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.8.2. Argentina
- 8.8.2.1. Key country dynamics
- 8.8.2.2. Regulatory framework
- 8.8.2.3. Competitive scenario
- 8.8.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.9. MEA
- 8.9.1. South Africa
- 8.9.1.1. Key country dynamics
- 8.9.1.2. Regulatory framework
- 8.9.1.3. Competitive scenario
- 8.9.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.9.2. Saudi Arabia
- 8.9.2.1. Key country dynamics
- 8.9.2.2. Regulatory framework
- 8.9.2.3. Competitive scenario
- 8.9.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.9.3. UAE
- 8.9.3.1. Key country dynamics
- 8.9.3.2. Regulatory framework
- 8.9.3.3. Competitive scenario
- 8.9.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
- 8.9.4. Kuwait
- 8.9.4.1. Key country dynamics
- 8.9.4.2. Regulatory framework
- 8.9.4.3. Competitive scenario
- 8.9.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company/Competition Categorization
- 9.3. Key company market share/position analysis, 2025
- 9.4. Company Profiles
- 9.4.1. Leica Biosystems Nussloch GmbH (subsidiary of Danaher)
- 9.4.1.1. Company overview
- 9.4.1.2. Financial performance
- 9.4.1.3. Product benchmarking
- 9.4.1.4. Strategic initiatives
- 9.4.2. Hamamatsu Photonics K.K.
- 9.4.2.1. Company overview
- 9.4.2.2. Financial performance
- 9.4.2.3. Product benchmarking
- 9.4.2.4. Strategic initiatives
- 9.4.3. Koninklijke Philips N.V.
- 9.4.3.1. Company overview
- 9.4.3.2. Financial performance
- 9.4.3.3. Product benchmarking
- 9.4.3.4. Strategic initiatives
- 9.4.4. Olympus Corporation
- 9.4.4.1. Company overview
- 9.4.4.2. Financial performance
- 9.4.4.3. Product benchmarking
- 9.4.4.4. Strategic initiatives
- 9.4.5. F. Hoffmann-La Roche Ltd.
- 9.4.5.1. Company overview
- 9.4.5.2. Financial performance
- 9.4.5.3. Product benchmarking
- 9.4.5.4. Strategic initiatives
- 9.4.6. Aiforia/ Aiforia Technologies PLC
- 9.4.6.1. Company overview
- 9.4.6.2. Financial performance
- 9.4.6.3. Product benchmarking
- 9.4.6.4. Strategic initiatives
- 9.4.7. Epredia (3DHISTECH Ltd.)
- 9.4.7.1. Company overview
- 9.4.7.2. Financial performance
- 9.4.7.3. Product benchmarking
- 9.4.7.4. Strategic initiatives
- 9.4.8. Visiopharm A/S
- 9.4.8.1. Company overview
- 9.4.8.2. Financial performance
- 9.4.8.3. Product benchmarking
- 9.4.8.4. Strategic initiatives
- 9.4.9. Proscia Inc.
- 9.4.9.1. Company overview
- 9.4.9.2. Financial performance
- 9.4.9.3. Product benchmarking
- 9.4.9.4. Strategic initiatives
- 9.4.10. Mindpeak GmbH
- 9.4.10.1. Company overview
- 9.4.10.2. Financial performance
- 9.4.10.3. Product benchmarking
- 9.4.10.4. Strategic initiatives
- 9.4.11. Akoya Biosciences, Inc. (a Quanterix company)
- 9.4.11.1. Company overview
- 9.4.11.2. Financial performance
- 9.4.11.3. Product benchmarking
- 9.4.11.4. Strategic initiatives
- 9.4.12. Paige AI, Inc.
- 9.4.12.1. Company overview
- 9.4.12.2. Financial performance
- 9.4.12.3. Product benchmarking
- 9.4.12.4. Strategic initiatives
- 9.4.13. CellaVision
- 9.4.13.1. Company overview
- 9.4.13.2. Financial performance
- 9.4.13.3. Product benchmarking
- 9.4.13.4. Strategic initiatives
- 9.4.14. aetherAI
- 9.4.14.1. Company overview
- 9.4.14.2. Financial performance
- 9.4.14.3. Product benchmarking
- 9.4.14.4. Strategic initiatives
- 9.4.15. Qritive
- 9.4.15.1. Company overview
- 9.4.15.2. Financial performance
- 9.4.15.3. Product benchmarking
- 9.4.15.4. Strategic initiatives
- 9.4.16. IBEX (IBEX MEDICAL ANALYTICS)
- 9.4.16.1. Company overview
- 9.4.16.2. Financial performance
- 9.4.16.3. Product benchmarking
- 9.4.16.4. Strategic initiatives
- 9.4.17. Nucleai, Inc.
- 9.4.17.1. Company overview
- 9.4.17.2. Financial performance
- 9.4.17.3. Product benchmarking
- 9.4.17.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
